研報掘金|中金:上調三生製藥目標價至13.5港元 創新產品進入收穫期
中金髮表報吿指,三生製藥去年收入91.08億元,按年升16.5%;淨利潤20.9億元,按年升34.9%,經調整經營性淨利潤23.19億元,按年升18.8%,業績好於該行預期,主要因核心品種穩健增長及聯營公司收益增長。
中金基本維持三生製藥2025年經調整淨利潤預測為24.07億元,引入2026年經調整淨利潤預測26.02億元。該行維持“跑贏行業”評級,由於近期港股流動性回暖和板塊估值中樞上升,上調目標價至13.5港元,另認為公司管線佈局豐富,創新產品進入收穫期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.